Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Platelet-Restricted Clonal Hematopoiesis

Nikolaos Sousos, Lauren Murphy, Sean Wen, Angela Hamblin, Sally-Ann Clark, Christina Simoglou Karali, Jessica Whittle, Zemin Ren, Haseeb Rahman, Nawshad Hayder, Akriti Rastogi, Michael Jacobs, Susan Shapiro, Bethan Psaila, Adam J Mead

Blood (2023) 142 (Supplement 1): 814.

https://doi.org/10.1182/blood-2023-188000

Published: 2023

Journal Articles

Chromothripsis Orchestrates Leukemic Transformation in Blast Phase MPN through Targetable Amplification of DYRK1A

Blood (2023) 142 (Supplement 1): 993.

https://doi.org/10.1182/blood-2023-178556

Published: 2023

Journal Articles

The SF3B1 K666 Hotspot Mutation Confers Unfavourable Disease Risk across Major Myeloid Neoplasm Subgroups

Jennifer O Sullivan, Amy Wood, Sean Wen, Angela Hamblin, Sonia Fox, Christina Yap, Mary Frances McMullin, Nicholas C. P. Cross, Claire N Harrison, Adam J Mead

Blood (2023) 142 (Supplement 1): 4552.

https://doi.org/10.1182/blood-2023-185043

Published: 2023

Journal Articles

Targeted NGS Panel Guides Risk-Adapted Treatment Intention in Newly Diagnosed Myeloma Patients

Gaurav Agarwal, Mohammad Kazeroun, Mirian Salazar, Khrystal McBean, Lisa Ferguson, Jemma Larham, Jaimal Kothari, Naser Ansari-Pour, Sally Moore, Eileen Boyle, Udo Oppermann, Karthik Ramasamy, Angela Hamblin, Anjan Thakurta, Sarah Gooding

Blood (2023) 142 (Supplement 1): 644.

https://doi.org/10.1182/blood-2023-182734

Published: 2023

Journal Articles

Cooperation between SF3B1 and JAK2 V617F Mutations Accelerates Fibrotic Progression in Myeloproliferative Neoplasms By Enhancing STAT1 Signaling

Jennifer O Sullivan, Sean Wen, Affaf Aliouat, Alba Rodriguez-Meira, Sally-Ann Clark, Neil Ashley, Amy Wood, Ramy Slama, Guanlin Wang, Angela Hamblin, Lauren Murphy, Christina Simoglou Karali, Charlotte K Brierley, Adam P Cribbs, Aimee Paterson, Claire N Harrison, Bethan Psaila, Adam J Mead

Blood (2023) 142 (Supplement 1): 861.

https://doi.org/10.1182/blood-2023-185118

Published: 2023

Journal Articles

Evidence of NF-ΚB Pathway Activation in Patients with Advanced, High Molecular Risk Myelofibrosis

Jennifer O'Sullivan, Aaron T. Gerds, Claire N. Harrison, Stephen T. Oh, Angela Hamblin, Sarah A Buckley, Alan F. List, Adam J. Mead

Blood (2021) 138 (Supplement 1): 3584.

https://doi.org/10.1182/blood-2021-149666

Published: 2021

Journal Articles

Molecular Characterisation of Participants in the Phazar Trial Reveals Prognostic Impact of Mutations in Advanced-Phase-MPN

Charlotte K Brierley, MRCP, MD, Alba Rodriguez-Meira, PhD, Matthew Bashton, PhD, Angela Hamblin, MD PhD, Rachel S Fletcher, PhD, Sonia Fox, Charlotte Gaskell, BSc, MSc, Aimee Jackson, BSc, MSc, Jennifer O'Sullivan, MD, Lauren C Murphy, Nikolaos Sousos, MDMSc, Amir Enshaei, PhD, Claire Harrison, DM, FRCP, FRCPath, Mark W. Drummond, PhD FRCPath, Steve Knapper, BMBCh, MRCP, FRCPath, DM, Bethan Psaila, MD PhD, Adam J. Mead, MD PhD

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-139520

Published: 2020

Journal Articles

The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib

Jennifer M. O’Sullivan, Angela Hamblin, Christina Yap, Sonia Fox, Rebecca Boucher, Anesh Panchal, Samah Alimam, Helene Dreau, Kieran Howard, Pauline Ware, Nicholas C. P. Cross, Mary Frances McMullin, Claire N. Harrison, Adam J. Mead

Blood (2019) 134 (23): 2107–2111.

https://doi.org/10.1182/blood.2019001861

Published: 2019

Includes: Supplemental data

Journal Articles

Clinical-Grade Whole Genome Sequencing Reproduces FISH Cytogenetics and Provides Actionable Data in Newly Diagnosed Myeloma - a Pilot Study from the UK 100,000 Genomes Project

Oliver Lomas, MD DPhil, MRCP, Sarah Gooding, MD PhD, Karthik Ramasamy, MD PhD, Angela Hamblin, MD PhD, Maite Cabes, PhD, Helene Marie-Pierre Dreau, PhD, Edward Wilson, FRCPath, MRCP

Blood (2019) 134 (Supplement_1): 3062.

https://doi.org/10.1182/blood-2019-125145

Published: 2019

Journal Articles

Molecular Analysis in the Pacritinib Dose-Finding PAC203 Study in Patients with Myelofibrosis Refractory or Intolerant to Ruxolitinib

Jennifer O'Sullivan, MD, Jason A Taylor, MD PhD, Aaron T. Gerds, MD MS, Sarah A Buckley, MD, Claire N Harrison, Professor, Stephen T. Oh, MD, Kieran Howard, Helene Marie-Pierre Dreau, PhD, Angela Hamblin, MD PhD, Adam J. Mead, MD PhD

Blood (2019) 134 (Supplement_1): 4214.

https://doi.org/10.1182/blood-2019-129254

Published: 2019

Journal Articles

Longitudinal Mutational Analysis in Hydroxycarbamide-Resistant/Intolerant Essential Thrombocythemia Treated on the Majic-ET Study

Jennifer O'Sullivan, MB BCh BAO, Angela Hamblin, MD PhD, Anesh Panchal, BSc, MSc, Christina Yap, MSci, PhD CStat, Sonia Fox, BSc, Samah Alimam, DHSC, MD, Helene Marie-Pierre Dreau, Kieran Howard, Pauline Ware, Samantha Baker, Nicholas C.P. Cross, Mary Frances McMullin, MD, Claire N. Harrison, MD DM, FRCP, PRCPath, Adam J. Mead, MD PhD

Blood (2018) 132 (Supplement 1): 1784.

https://doi.org/10.1182/blood-2018-99-118220

Published: 2018

Journal Articles

Spliceosome Mutations Are Common in MPN-Associated Myelofibrosis with RBC-Transfusion-Dependence and Correlate with Response to Pomalidomide

Blood (2018) 132 (Supplement 1): 3037.

https://doi.org/10.1182/blood-2018-99-119402

Published: 2018

Journal Articles

Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations

Blood (2018) 132 (12): 1225–1240.

https://doi.org/10.1182/blood-2018-04-843771

Published: 2018

Includes: Supplemental data

Journal Articles

Molecular and Functional Characterization of Disease-Propagating Stem Cells in Juvenile Myelomonocytic Leukemia

Eleni Louka, MD, Benjamin Povinelli, PhD, Alba Rodriguez-Meira, Gemma Buck, BSc, Angela Hamblin, MD PhD, Christopher Booth, Anindita Roy, MD PhD, Natalina Elliott, PhD, Deena Iskander, MD, Josu de la Fuente, FRCP, PhD FRCPath, Nicholas James Fordham, MBBS, BSc, Sorcha Isabella Obyrne, Sarah Inglott, Anupama Gopala Rao, MB, MRCP, MRCPath, Irene Roberts, MD, Adam J Mead, MD PhD

Blood (2017) 130 (Supplement 1): 379.

https://doi.org/10.1182/blood.V130.Suppl_1.379.379

Published: 2017

Journal Articles

A Phase II Study to Determine the Safety and Efficacy of the Dual m-TORC Inhibitor AZD2014 and to Investigate Additional Toxicities in Combination with Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Toby A. Eyre, MBBChir, MRCP, Catherine Hildyard, MRCP, BA, Anesh Panchal, BSc, MSc, Aimee E Houlton, BSc, MSc, Louise Hopkins, BSc, MRes, Angela Hamblin, MD PhD, Kim Linton, MBChB PhD, Andrew Pettitt, FRCPath, PhD, Simon Rule, MD, Kate Cwynarski, PhD MD, Sally Barrington, MBBS, MSc, FRCP, FRCR, MD, David Wrench, MA, MBBChir, FRCPath, PhD, Andrew Davies, PhD, Graham Collins, MD PhD

Blood (2017) 130 (Supplement 1): 5210.

https://doi.org/10.1182/blood.V130.Suppl_1.5210.5210

Published: 2017

Journal Articles

Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide

Blood (2017) 130 (17): 1889–1897.

https://doi.org/10.1182/blood-2017-05-785790

Published: 2017

Includes: Supplemental data

Journal Articles

Correlation Between Treatment Outcomes, Baseline Characteristics and Molecular Responses in the Majic Study Which Compared Ruxolitinib to Best Available Therapy in Essential Thrombocythemia

Blood (2016) 128 (22): 1929.

https://doi.org/10.1182/blood.V128.22.1929.1929

Published: 2016

Journal Articles

Provision of Long-Term Monitoring and Late Effects Services Following Hematopoietic Cell Transplantation (HCT): A Survey of European Programs By the Complications and Quality of Life Working Party of the EBMT

Nina Salooja, DM, FRCP, FRCPath, Steffie van der Werf, MSc, Maura Faraci, MD, Angela Hamblin, MDPhD, Anja van Biezen, Grzegorz W. Basak, MD PhD, Rafael F. Duarte, MD PhD

Blood (2016) 128 (22): 4607.

https://doi.org/10.1182/blood.V128.22.4607.4607

Published: 2016

Journal Articles

Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL

Blood (2015) 126 (18): 2110–2117.

https://doi.org/10.1182/blood-2015-05-647578

Published: 2015

Includes: Supplemental data

Journal Articles

The Identification of Further Minimal Regions of Overlap in Chronic Lymphocytic Leukemia Using High-Resolution SNP Arrays

Samantha JL Knight, PhD CBiol, MSB, FRCPath, Ruth Clifford, MD, Pauline Robbe, MSc, Sara DC Ramos, MSc, Adam Burns, BSc, Adele T Timbs, MSc, Reem Alsolami, BSc, Susanne Weller, PhD, Angela Hamblin, MDPhD, Joanne Mason, PhD, Melanie Oates, PhD, Michalis Titsias, PhD, Christopher Yau, DPhil, Chris C Holmes, PhD, Andrew R Pettitt, FRCP, PhD, Peter Hillmen, MB, ChB, PhD, Jenny Taylor, DPhil, Anna Shuh, MD PhD FRCP, FRCPath

Blood (2014) 124 (21): 3315.

https://doi.org/10.1182/blood.V124.21.3315.3315

Published: 2014

NARROW

Platelet-Restricted Clonal Hematopoiesis

Chromothripsis Orchestrates Leukemic Transformation in Blast Phase MPN through Targetable Amplification of DYRK1A

The SF3B1 K666 Hotspot Mutation Confers Unfavourable Disease Risk across Major Myeloid Neoplasm Subgroups

Targeted NGS Panel Guides Risk-Adapted Treatment Intention in Newly Diagnosed Myeloma Patients

Cooperation between SF3B1 and JAK2 V617F Mutations Accelerates Fibrotic Progression in Myeloproliferative Neoplasms By Enhancing STAT1 Signaling

Evidence of NF-ΚB Pathway Activation in Patients with Advanced, High Molecular Risk Myelofibrosis

Molecular Characterisation of Participants in the Phazar Trial Reveals Prognostic Impact of Mutations in Advanced-Phase-MPN

The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib

Clinical-Grade Whole Genome Sequencing Reproduces FISH Cytogenetics and Provides Actionable Data in Newly Diagnosed Myeloma - a Pilot Study from the UK 100,000 Genomes Project

Molecular Analysis in the Pacritinib Dose-Finding PAC203 Study in Patients with Myelofibrosis Refractory or Intolerant to Ruxolitinib

Longitudinal Mutational Analysis in Hydroxycarbamide-Resistant/Intolerant Essential Thrombocythemia Treated on the Majic-ET Study

Spliceosome Mutations Are Common in MPN-Associated Myelofibrosis with RBC-Transfusion-Dependence and Correlate with Response to Pomalidomide

Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations

Molecular and Functional Characterization of Disease-Propagating Stem Cells in Juvenile Myelomonocytic Leukemia

A Phase II Study to Determine the Safety and Efficacy of the Dual m-TORC Inhibitor AZD2014 and to Investigate Additional Toxicities in Combination with Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide

Correlation Between Treatment Outcomes, Baseline Characteristics and Molecular Responses in the Majic Study Which Compared Ruxolitinib to Best Available Therapy in Essential Thrombocythemia

Provision of Long-Term Monitoring and Late Effects Services Following Hematopoietic Cell Transplantation (HCT): A Survey of European Programs By the Complications and Quality of Life Working Party of the EBMT

Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL

The Identification of Further Minimal Regions of Overlap in Chronic Lymphocytic Leukemia Using High-Resolution SNP Arrays

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only